Trial · NCT03271047
Results by group1,179
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 1,179
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Phase 1b: Number of Participants With Dose-Limiting Toxicities (DLT) | Phase 1b: Nivolumab+Binimetinib | 1 | Participants | ||
| Phase 1b: Number of Participants With Dose-Limiting Toxicities (DLT) | Phase 1b: Nivolumab+Ipilimumab+Binimetinib | 2 | Participants | ||
| Phase 2: Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1 | Phase 2: Nivolumab+Binimetinib | 0.0 | 95% Confidence Interval NA to NA | Percentage of participants | |
| Phase 2: Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1 | Phase 2: Nivolumab+Ipilimumab+Binimetinib | 7.4 | 95% Confidence Interval 0.9 to 24.3 | Percentage of participants | |
| Phase 1b: Objective Response Rate (ORR) Per RECIST v1.1 | Phase 1b: Nivolumab+Binimetinib | 0.0 | 95% Confidence Interval NA to NA | Percentage of participants | |
| Phase 1b: Objective Response Rate (ORR) Per RECIST v1.1 | Phase 1b: Nivolumab+Ipilimumab+Binimetinib | 0.0 | 95% Confidence Interval NA to NA | Percentage of participants | |
| Duration of Response (DOR) as Per RECIST v1.1 | Phase 2: Nivolumab+Ipilimumab+Binimetinib | 11.4 | 95% Confidence Interval 7.5 to 15.2 | Months | |
| Percentage of Participants With Complete Response as Per RECIST v1.1 | Phase 1b: Nivolumab+Binimetinib | 0 | Percentage of participants | ||
| Percentage of Participants With Complete Response as Per RECIST v1.1 | Phase 1b: Nivolumab+Ipilimumab+Binimetinib | 0 | Percentage of participants | ||
| Percentage of Participants With Complete Response as Per RECIST v1.1 | Phase 2: Nivolumab+Binimetinib | 0 | Percentage of participants | ||
| Percentage of Participants With Complete Response as Per RECIST v1.1 | Phase 2: Nivolumab+Ipilimumab+Binimetinib | 0 | Percentage of participants | ||
| Number of Participants With Treatment-Emergent Adverse Events (TEAE) Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03 | Phase 1b: Nivolumab+Binimetinib | Treatment emergent AEs- All grades | 10 | Participants | |
| Number of Participants With Treatment-Emergent Adverse Events (TEAE) Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03 | Phase 1b: Nivolumab+Ipilimumab+Binimetinib | Treatment emergent AEs- All grades | 11 | Participants | |
| Number of Participants With Treatment-Emergent Adverse Events (TEAE) Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03 | Phase 2: Nivolumab+Binimetinib | Treatment emergent AEs- All grades | 27 | Participants | |
| Number of Participants With Treatment-Emergent Adverse Events (TEAE) Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03 | Phase 2: Nivolumab+Ipilimumab+Binimetinib | Treatment emergent AEs- All grades | 27 | Participants | |
| Number of Participants With Treatment-Emergent Adverse Events (TEAE) Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03 | Phase 1b: Nivolumab+Binimetinib | Treatment emergent SAEs- All grades | 5 | Participants | |
| Number of Participants With Treatment-Emergent Adverse Events (TEAE) Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03 | Phase 1b: Nivolumab+Ipilimumab+Binimetinib | Treatment emergent SAEs- All grades | 6 | Participants | |
| Number of Participants With Treatment-Emergent Adverse Events (TEAE) Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03 | Phase 2: Nivolumab+Binimetinib | Treatment emergent SAEs- All grades | 12 | Participants | |
| Number of Participants With Treatment-Emergent Adverse Events (TEAE) Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03 | Phase 2: Nivolumab+Ipilimumab+Binimetinib | Treatment emergent SAEs- All grades | 11 | Participants | |
| Number of Participants With Treatment-Emergent Adverse Events (TEAE) Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03 | Phase 1b: Nivolumab+Binimetinib | Treatment emergent AEs- Grade 3/4 | 6 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03271047/results